GSK chief says RSV vaccine will start off slower than shingles shot

GlaxoSmithKline CEO Emma Walmsley on Wednesday said she expects uptake for the company's new RSV vaccine to start off slower than it did for its blockbuster shingles shot. But she is confident that the new vaccine will drive future sales. "I think the uptake on this we need to watch for through…#emmawalmsley #rsv #gsk #shingrix
Source: Reuters: Health - Category: Consumer Health News Source Type: news